Profound Medical (TSE:PRN) Reaches New 12-Month High – Still a Buy?

Profound Medical Corp. (TSE:PRN)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as C$11.45 and last traded at C$11.28, with a volume of 20157 shares changing hands. The stock had previously closed at C$10.67.

Profound Medical Price Performance

The company has a quick ratio of 14.98, a current ratio of 6.12 and a debt-to-equity ratio of 20.05. The company has a market capitalization of C$424.99 million, a P/E ratio of -8.87 and a beta of 1.19. The company’s 50-day simple moving average is C$9.53 and its 200 day simple moving average is C$8.11.

Profound Medical (TSE:PRN) last released its quarterly earnings results on Thursday, November 13th. The company reported C$0.26 EPS for the quarter. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. The company had revenue of C$7.36 million for the quarter. As a group, sell-side analysts expect that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.